A company called Advaxis is planning to test a new form of prostate cancer immunotherapy (ADXS-PSA) in combination with an investigational drug called pembrolizumab (an anti-PD-1 immune checkpoint inhibitor) in men with previously treated, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADXS-PSA, castration-resistant, immunotherapy, mCRPC, metastatic, PD-1, pembrolizumab | 6 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 